TERM ID="NYU_TERM_1" STRING="CS" FREQUENCY=1 START=755 END=757 LEMMA="CLINICALLY SIGNIFICANT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_2" STRING="CS exacerbations" FREQUENCY=2 START=906 END=922 LEMMA="CS EXACERBATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_3" STRING="CS exacerbations" FREQUENCY=2 START=1034 END=1050 LEMMA="CS EXACERBATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_4" STRING="CSS" FREQUENCY=1 START=794 END=797 LEMMA="CLINICALLY SIGNIFICANT SEVERE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_5" STRING="CSS exacerbations" FREQUENCY=1 START=957 END=974 LEMMA="CSS EXACERBATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="Clinical Excellence" FREQUENCY=1 START=416 END=435 LEMMA="CLINICAL EXCELLENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="IA-05 trial" FREQUENCY=1 START=680 END=691 LEMMA="IA-05 TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="Novartis Pharmaceutical UK" FREQUENCY=1 START=344 END=370 LEMMA="NOVARTIS PHARMACEUTICAL UK" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_9" STRING="Omalizumab" FREQUENCY=1 START=0 END=10 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_10" STRING="Omalizumab therapy" FREQUENCY=1 START=814 END=832 LEMMA="OMALIZUMAB THERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="Union Population" FREQUENCY=1 START=653 END=669 LEMMA="UNION POPULATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="allergic asthma" FREQUENCY=2 START=50 END=65 LEMMA="ALLERGIC ASTHMA" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_13" STRING="allergic asthma" FREQUENCY=2 START=2021 END=2036 LEMMA="ALLERGIC ASTHMA" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_14" STRING="asthma" FREQUENCY=1 START=268 END=274 LEMMA="ASTHMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="baseline" FREQUENCY=1 START=1130 END=1138 LEMMA="BASELINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="clinical effectiveness" FREQUENCY=1 START=169 END=191 LEMMA="CLINICAL EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="clinically significant" FREQUENCY=1 START=731 END=753 LEMMA="CLINICALLY SIGNIFICANT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_18" STRING="clinically significant severe" FREQUENCY=1 START=763 END=792 LEMMA="CLINICALLY SIGNIFICANT SEVERE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_19" STRING="cost-effectiveness" FREQUENCY=1 START=196 END=214 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="cost-effectiveness of omalizumab" FREQUENCY=1 START=196 END=228 LEMMA="OMALIZUMAB COST-EFFECTIVENESS" LEMMA_FREQUENCY=1 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_21" STRING="de novo economic evaluation" FREQUENCY=1 START=1264 END=1291 LEMMA="DE NOVO ECONOMIC EVALUATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="decision problem" FREQUENCY=1 START=1399 END=1415 LEMMA="DECISION PROBLEM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="economic evidence" FREQUENCY=1 START=1326 END=1343 LEMMA="ECONOMIC EVIDENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="economic model" FREQUENCY=1 START=1349 END=1363 LEMMA="ECONOMIC MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="evidence review group report" FREQUENCY=1 START=131 END=159 LEMMA="EVIDENCE REVIEW GROUP REPORT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="evidence submission" FREQUENCY=1 START=319 END=338 LEMMA="EVIDENCE SUBMISSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="exacerbations" FREQUENCY=2 START=799 END=812 LEMMA="EXACERBATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_28" STRING="exacerbations" FREQUENCY=2 START=1104 END=1117 LEMMA="EXACERBATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_29" STRING="incremental cost-effectiveness ratios" FREQUENCY=1 START=1679 END=1716 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="life-year" FREQUENCY=1 START=1763 END=1772 LEMMA="LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="manufacturer" FREQUENCY=2 START=498 END=511 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_32" STRING="manufacturer" FREQUENCY=2 START=1144 END=1156 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_33" STRING="omalizumab" FREQUENCY=4 START=218 END=228 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_34" STRING="omalizumab" FREQUENCY=4 START=1215 END=1225 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_35" STRING="omalizumab" FREQUENCY=4 START=1459 END=1469 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_36" STRING="omalizumab" FREQUENCY=4 START=1952 END=1962 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_37" STRING="one-way sensitivity analyses" FREQUENCY=1 START=1882 END=1910 LEMMA="ONE-WAY SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="preplanned subgroup IA-05 EUP" FREQUENCY=1 START=613 END=642 LEMMA="PREPLANNED SUBGROUP IA-05 EUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="published cost-effectiveness studies" FREQUENCY=1 START=1175 END=1211 LEMMA="PUBLISHED COST-EFFECTIVENESS STUDY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_40" STRING="published cost-effectiveness studies of omalizumab" FREQUENCY=1 START=1175 END=1225 LEMMA="OMALIZUMAB PUBLISHED COST-EFFECTIVENESS STUDY" LEMMA_FREQUENCY=1 HEAD_TERM="published cost-effectiveness studies" HEAD_LEMMA="PUBLISHED COST-EFFECTIVENESS STUDY"
TERM ID="NYU_TERM_41" STRING="subgroup" FREQUENCY=1 START=1607 END=1615 LEMMA="SUBGROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="technology appraisal process" FREQUENCY=1 START=465 END=493 LEMMA="TECHNOLOGY APPRAISAL PROCESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="year prior" FREQUENCY=1 START=1648 END=1658 LEMMA="YEAR PRIOR" LEMMA_FREQUENCY=1
